

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | |
|---|--|---|--|
| (51) International Patent Classification ⁶ : C07D 235/06, 401/10, 403/10, A61K 31/445, 31/415 // (C07D 401/10, 235:00, 211:00) (C07D 403/10, 235:00, 233:00) | | A1 | (11) International Publication Number: WO 98/34923 (43) International Publication Date: 13 August 1998 (13.08.98) |
| (21) International Application Number: PCT/GB98/00322 (22) International Filing Date: 2 February 1998 (02.02.98) (30) Priority Data: 9702524.1 7 February 1997 (07.02.97) GB | | (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). | |
| (71) Applicant (<i>for all designated States except US</i>): MERCK SHARP & DOHME LIMITED [GB/GB]; Hertford Road, Hoddesdon, Hertfordshire EN11 9BU (GB). (72) Inventors; and (75) Inventors/Applicants (<i>for US only</i>): HARRISON, Timothy [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). SPAREY, Timothy, Jason [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). TEALL, Martin, Richard [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). (74) Agent: THOMPSON, John; Merck & Co., Inc., European Patent Dept., Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). | | Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> | |
| (54) Title: PHENYLBENZIMIDAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | | | |
| (57) Abstract <p>A class of 1-phenylbenzimidazole derivatives, substituted at the <i>meta</i> position of the phenyl ring by a methylene-, carbonyl- or thiocarbonyl-linked amine moiety, are selective ligands for GABA_A receptors, in particular having high affinity for the $\alpha 2$ and/or $\alpha 3$ subunit thereof, and are accordingly of benefit in the treatment and/or prevention of disorders of the central nervous system, including anxiety and convulsions.</p> | | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|---------------------------------------|----|---|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | HU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MW | Malawi | UG | Uganda |
| BY | Belarus | IS | Iceland | MX | Mexico | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NL | Netherlands | VN | Viet Nam |
| CG | Congo | KE | Kenya | NO | Norway | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | KR | Republic of Korea | PT | Portugal | | |
| CN | China | KZ | Kazakhstan | RO | Romania | | |
| CU | Cuba | LC | Saint Lucia | RU | Russian Federation | | |
| CZ | Czech Republic | LI | Liechtenstein | SD | Sudan | | |
| DE | Germany | LK | Sri Lanka | SE | Sweden | | |
| DK | Denmark | LR | Liberia | SG | Singapore | | |
| EE | Estonia | | | | | | |

**PHENYLBENZIMIDAZOLE DERIVATIVES AS LIGANDS FOR
GABA RECEPTORS**

The present invention relates to a class of substituted benzimidazole derivatives and to their use in therapy. More particularly, this invention is concerned with substituted 1-phenylbenzimidazole derivatives which are ligands for GABA_A receptors and are therefore useful in the therapy of deleterious mental states.

Receptors for the major inhibitory neurotransmitter, gamma-aminobutyric acid (GABA), are divided into two main classes: (1) GABA_A receptors, which are members of the ligand-gated ion channel superfamily; and (2) GABA_B receptors, which may be members of the G-protein linked receptor superfamily. Since the first cDNAs encoding individual GABA_A receptor subunits were cloned the number of known members of the mammalian family has grown to include at least six α subunits, four β subunits, three γ subunits, one δ subunit, one ε subunit and two ρ subunits.

Although knowledge of the diversity of the GABA_A receptor gene family represents a huge step forward in our understanding of this ligand-gated ion channel, insight into the extent of subtype diversity is still at an early stage. It has been indicated that an α subunit, a β subunit and a γ subunit constitute the minimum requirement for forming a fully functional GABA_A receptor expressed by transiently transfecting cDNAs into cells. As indicated above, δ , ε and ρ subunits also exist, but are present only to a minor extent in GABA_A receptor populations.

Studies of receptor size and visualisation by electron microscopy conclude that, like other members of the ligand-gated ion channel family, the native GABA_A receptor exists in pentameric form. The selection of at least one α , one β and one γ subunit from a repertoire of seventeen allows for the possible existence of more than 10,000 pentameric subunit combinations. Moreover, this calculation overlooks the additional

permutations that would be possible if the arrangement of subunits around the ion channel had no constraints (i.e. there could be 120 possible variants for a receptor composed of five different subunits).

Receptor subtype assemblies which do exist include, amongst many
5 others, $\alpha 1\beta 2\gamma 2$, $\alpha 2\beta 2/3\gamma 2$, $\alpha 3\beta \gamma 2/3$, $\alpha 2\beta \gamma 1$, $\alpha 4\beta \delta$, $\alpha 5\beta 3\gamma 2/3$, $\alpha 6\beta \gamma 2$ and $\alpha 6\beta \delta$.
Subtype assemblies containing an $\alpha 1$ subunit are present in most areas of
the brain and are thought to account for over 40% of GABA_A receptors in
the rat. Subtype assemblies containing $\alpha 2$ and $\alpha 3$ subunits respectively
are thought to account for about 25% and 17% of GABA_A receptors in the
10 rat. Subtype assemblies containing an $\alpha 5$ subunit are expressed
predominantly in the hippocampus and cortex and are thought to
represent about 4% of GABA_A receptors in the rat.

A characteristic property of all known GABA_A receptors is the
presence of a number of modulatory sites, one of which is the
15 benzodiazepine (BZ) binding site. The BZ binding site is the most explored
of the GABA_A receptor modulatory sites, and is the site through which
anxiolytic drugs such as diazepam and temazepam exert their effect.
Before the cloning of the GABA_A receptor gene family, the benzodiazepine
binding site was historically subdivided into two subtypes, BZ1 and BZ2,
20 on the basis of radioligand binding studies. The BZ1 subtype has been
shown to be pharmacologically equivalent to a GABA_A receptor comprising
the $\alpha 1$ subunit in combination with a β subunit and $\gamma 2$. This is the most
abundant GABA_A receptor subtype, and is believed to represent almost
half of all GABA_A receptors in the brain.

25 Two other major populations are the $\alpha 2\beta \gamma 2$ and $\alpha 3\beta \gamma 2/3$ subtypes.
Together these constitute approximately a further 35% of the total GABA_A
receptor repertoire. Pharmacologically this combination appears to be
equivalent to the BZ2 subtype as defined previously by radioligand
binding, although the BZ2 subtype may also include certain $\alpha 5$ -containing
30 subtype assemblies. The physiological role of these subtypes has hitherto

been unclear because no sufficiently selective agonists or antagonists were known.

It is now believed that agents acting as BZ agonists at $\alpha 1\beta\gamma 2$, $\alpha 2\beta\gamma 2$ or $\alpha 3\beta\gamma 2$ subunits will possess desirable anxiolytic properties. Compounds
5 which are modulators of the benzodiazepine binding site of the GABA_A receptor by acting as BZ agonists are referred to hereinafter as "GABA_A receptor agonists". The $\alpha 1$ -selective GABA_A receptor agonists alpidem and zolpidem are clinically prescribed as hypnotic agents, suggesting that at least some of the sedation associated with known anxiolytic drugs which
10 act at the BZ1 binding site is mediated through GABA_A receptors containing the $\alpha 1$ subunit. Accordingly, it is considered that GABA_A receptor agonists which interact more favourably with the $\alpha 2$ and/or $\alpha 3$ subunit than with $\alpha 1$ will be effective in the treatment of anxiety with a reduced propensity to cause sedation. Also, agents which are antagonists
15 or inverse agonists at $\alpha 1$ might be employed to reverse sedation or hypnosis caused by $\alpha 1$ agonists.

The compounds of the present invention, being selective ligands for GABA_A receptors, are therefore of use in the treatment and/or prevention of a variety of disorders of the central nervous system. Such disorders
20 include anxiety disorders, such as panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, animal and other phobias including social phobias, obsessive-compulsive disorder, stress disorders including post-traumatic and acute stress disorder, and generalized or substance-induced anxiety disorder; neuroses; convulsions;
25 migraine; depressive or bipolar disorders, for example single-episode or recurrent major depressive disorder, dysthymic disorder, bipolar I and bipolar II manic disorders, and cyclothymic disorder; psychotic disorders including schizophrenia; neurodegeneration arising from cerebral ischemia; attention deficit hyperactivity disorder; and disorders of
30 circadian rhythm, e.g. in subjects suffering from the effects of jet lag or shift work.

Further disorders for which selective ligands for GABA_A receptors may be of benefit include pain and nociception; emesis, including acute, delayed and anticipatory emesis, in particular emesis induced by chemotherapy or radiation, as well as post-operative nausea and vomiting; 5 and muscle spasm or spasticity, e.g. in paraplegic patients. Selective ligands for GABA_A receptors may also be effective as pre-medication prior to anaesthesia or minor procedures such as endoscopy, including gastric endoscopy.


EP-A-0616807 describes a class of benzimidazole derivatives 10 substituted at the 1-position by *inter alia* a phenyl moiety which in turn is substituted at the *meta* position by an optionally substituted phenyl, benzimidazolyl or 5- or 6-membered monocyclic heteroaromatic group, or by an alkoxy or acyl group. These compounds are stated to possess potent benzodiazepine receptor affinity, and thus to be useful in the treatment of 15 convulsions, anxiety, sleep disorders, memory disorders and other disorders sensitive to benzodiazepine receptor binding activity. There is, however, no disclosure nor any suggestion in EP-A-0616807 that the precisely defined range of substituents prescribed for the *meta* position of the phenyl moiety might be replaced by any other substituent.

20 The present invention provides a class of benzimidazole derivatives which possess desirable binding properties at various GABA_A receptor subtypes. The compounds in accordance with the present invention have good affinity as ligands for the α 2 and/or α 3 subunit of the human GABA_A receptor. The compounds of this invention may interact more favourably 25 with the α 2 and/or α 3 subunit than with the α 1 subunit. Desirably, the compounds of the invention will exhibit functional selectivity in terms of a selective efficacy for the α 2 and/or α 3 subunit relative to the α 1 subunit.

The compounds of the present invention are GABA_A receptor 30 subtype ligands having a binding affinity (K_i) for the α 2 and/or α 3 subunit, as measured in the assay described hereinbelow, of 100 nM or less, typically of 50 nM or less, and ideally of 10 nM or less. The compounds in

accordance with this invention may possess at least a 2-fold, suitably at least a 5-fold, and advantageously at least a 10-fold, selective affinity for the α_2 and/or α_3 subunit relative to the α_1 subunit. However, compounds which are not selective in terms of their binding affinity for the α_2 and/or α_3 subunit relative to the α_1 subunit are also encompassed within the scope of the present invention; such compounds will desirably exhibit functional selectivity in terms of a selective efficacy for the α_2 and/or α_3 subunit relative to the α_1 subunit.

The present invention provides a compound of formula I, or a salt or
10 prodrug thereof:



(I)

wherein

15 Y represents a methylene (CH_2), carbonyl ($\text{C}=\text{O}$) or thiocarbonyl ($\text{C}=\text{S}$) linkage;

20 R^1 and R^2 independently represent hydrogen, hydrocarbon or a heterocyclic group; or R^1 and R^2 , together with the intervening nitrogen atom, represent an optionally substituted heterocyclic ring selected from azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl and imidazolyl;

25 R^3 represents hydrogen, hydrocarbon, a heterocyclic group, halogen, cyano, trifluoromethyl, nitro, $-\text{OR}^a$, $-\text{SR}^a$, $-\text{SOR}^a$, $-\text{SO}_2\text{R}^a$, $-\text{SO}_2\text{NR}^a\text{R}^b$, $-\text{NR}^a\text{R}^b$, $-\text{NR}^a\text{COR}^b$, $-\text{NR}^a\text{CO}_2\text{R}^b$, $-\text{COR}^a$, $-\text{CO}_2\text{R}^a$, $-\text{CONR}^a\text{R}^b$ or $-\text{CR}^a=\text{NOR}^b$; and

R^a and R^b independently represent hydrogen, hydrocarbon or a heterocyclic group.

The present invention also provides a compound of formula I as defined above, or a salt or prodrug thereof, wherein

5 R¹ and R² independently represent hydrogen, hydrocarbon or a heterocyclic group; or R¹ and R², together with the intervening nitrogen atom, represent an optionally substituted heterocyclic ring selected from azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl and thiomorpholinyl; and

10 Y and R³ are as defined above.

Where R¹ and R², together with the intervening nitrogen atom, represent an optionally substituted heterocyclic ring, this ring may be substituted by one or more, preferably one or two, substituents. Examples of optional substituents on the heterocyclic ring include C₁₋₆ alkyl and hydroxy. Typical substituents include methyl and hydroxy.

For use in medicine, the salts of the compounds of formula I will be pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of the compounds according to the invention or of their pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, methanesulphonic acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.

Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g. sodium or potassium salts; alkaline earth metal salts, e.g. calcium or magnesium salts; and salts formed with suitable organic ligands, e.g. quaternary ammonium salts.

The term "hydrocarbon" as used herein includes straight-chained, branched and cyclic groups containing up to 18 carbon atoms, suitably up to 15 carbon atoms, and conveniently up to 12 carbon atoms. Suitable hydrocarbon groups include C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl(C₁₋₆)alkyl, indanyl, aryl and aryl(C₁₋₆)alkyl.

The expression "a heterocyclic group" as used herein includes cyclic groups containing up to 18 carbon atoms and at least one heteroatom preferably selected from oxygen, nitrogen and sulphur. The heterocyclic group suitably contains up to 15 carbon atoms and conveniently up to 12 carbon atoms, and is preferably linked through carbon. Examples of suitable heterocyclic groups include C₃₋₇ heterocycloalkyl, C₃₋₇ heterocycloalkyl(C₁₋₆)alkyl, heteroaryl and heteroaryl(C₁₋₆)alkyl groups.

Suitable alkyl groups include straight-chained and branched alkyl groups containing from 1 to 6 carbon atoms. Typical examples include methyl and ethyl groups, and straight-chained or branched propyl, butyl and pentyl groups. Particular alkyl groups are methyl, ethyl, *n*-propyl, isopropyl, isobutyl, *tert*-butyl and 2,2-dimethylpropyl. Derived expressions such as "C₁₋₆ alkoxy", "C₁₋₆ alkylamino" and "C₁₋₆ alkylsulphonyl" are to be construed accordingly.

Suitable alkenyl groups include straight-chained and branched alkenyl groups containing from 2 to 6 carbon atoms. Typical examples include vinyl, allyl and dimethylallyl groups.

Suitable alkynyl groups include straight-chained and branched alkynyl groups containing from 2 to 6 carbon atoms. Typical examples include ethynyl and propargyl groups.

Suitable cycloalkyl groups include groups containing from 3 to 7 carbon atoms. Particular cycloalkyl groups are cyclopropyl and cyclohexyl.

Typical examples of C₃₋₇ cycloalkyl(C₁₋₆)alkyl groups include cyclopropylmethyl, cyclohexylmethyl and cyclohexylethyl.

Particular indanyl groups include indan-1-yl and indan-2-yl.

Particular aryl groups include phenyl and naphthyl.

Particular aryl(C₁₋₆)alkyl groups include benzyl, phenylethyl, phenylpropyl and naphthylmethyl.

Suitable heterocycloalkyl groups include azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl and thiomorpholinyl groups.

5 Suitable heteroaryl groups include pyridinyl, quinolinyl, isoquinolinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyranyl, furyl, benzofuryl, dibenzofuryl, thienyl, benzthienyl, pyrrolyl, indolyl, pyrazolyl, indazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, benzimidazolyl, oxadiazolyl, thiadiazolyl, triazolyl and tetrazolyl groups.

10 The expression "heteroaryl(C₁₋₆)alkyl" as used herein includes furylmethyl, furylethyl, thienylmethyl, thienylethyl, oxazolylmethyl, oxazolylethyl, thiazolylmethyl, thiazolylethyl, imidazolylmethyl, imidazolylethyl, oxadiazolylmethyl, oxadiazolylethyl, thiadiazolylmethyl, thiadiazolylethyl, triazolylmethyl, triazolylethyl, tetrazolylmethyl, tetrazolylethyl, pyridinylmethyl, pyridinylethyl, pyrimidinylmethyl, pyrazinylmethyl, quinolinylmethyl and isoquinolinylmethyl.

The hydrocarbon and heterocyclic groups may in turn be optionally substituted by one or more groups selected from C₁₋₆ alkyl, adamantyl, phenyl, halogen, C₁₋₆ haloalkyl, C₁₋₆ aminoalkyl, trifluoromethyl, hydroxy, 20 C₁₋₆ alkoxy, aryloxy, keto, C₁₋₃ alkyleneoxy, nitro, cyano, carboxy, C₂₋₆ alkoxycarbonyl, C₂₋₆ alkoxycarbonyl(C₁₋₆)alkyl, C₂₋₆ alkylcarbonyloxy, arylcarbonyloxy, aminocarbonyloxy, C₂₋₆ alkylcarbonyl, arylcarbonyl, C₁₋₆ alkylthio, C₁₋₆ alkylsulphinyl, C₁₋₆ alkylsulphonyl, arylsulphonyl, -NR^vR^w, -NR^vCOR^w, -NR^vCO₂R^w, -NR^vSO₂R^w, -CH₂NR^vSO₂R^w, -NHCONR^vR^w, 25 -CONR^vR^w, -SO₂NR^vR^w and -CH₂SO₂NR^vR^w, in which R^v and R^w independently represent hydrogen, C₁₋₆ alkyl, aryl or aryl(C₁₋₆)alkyl.

The term "halogen" as used herein includes fluorine, chlorine, bromine and iodine, especially fluorine.

30 The present invention includes within its scope prodrugs of the compounds of formula I above. In general, such prodrugs will be functional derivatives of the compounds of formula I which are readily

convertible *in vivo* into the required compound of formula I. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in *Design of Prodrugs*, ed. H. Bundgaard, Elsevier, 1985.

5 Where the compounds according to the invention have at least one asymmetric centre, they may accordingly exist as enantiomers. Where the compounds according to the invention possess two or more asymmetric centres, they may additionally exist as diastereoisomers. It is to be understood that all such isomers and mixtures thereof in any proportion
10 are encompassed within the scope of the present invention.

Suitable values for the substituents R¹ and R² include hydrogen, C₁₋₆ alkyl, aryl(C₁₋₆)alkyl and heteroaryl(C₁₋₆)alkyl, any of which groups may be optionally substituted. Typical substituents include C₁₋₆ alkyl, C₁₋₆ alkoxy and halogen.


15 Particular values of R¹ and R² include hydrogen, methyl, ethyl and pyridinylmethyl.

Suitably, one of R¹ and R² is other than hydrogen.

Where R¹ and R², together with the intervening nitrogen atom, represent an optionally substituted heterocyclic ring, this ring is suitably a
20 piperidinyl, morpholinyl, thiomorpholinyl or imidazolyl ring, any of which rings may be unsubstituted or substituted by one or more, preferably one or two, substituents, typically hydroxy. In this context, typical values for the -NR¹R² moiety include hydroxy-piperidinyl, morpholinyl, thiomorpholinyl and imidazolyl, preferably morpholinyl.

25 Suitable values for the substituent R³ include hydrogen, halogen, cyano, nitro, trifluoromethyl, pyrrolyl, furyl, isoxazolyl, amino, C₁₋₆ alkylamino, di(C₁₋₆)alkylamino, C₁₋₆ alkyl, C₁₋₆ alkoxy, aryl(C₁₋₆)alkoxy, C₂₋₆ alkylcarbonyl, C₁₋₆ alkylsulphonyl and -CR⁴=NOR⁵, in which R⁴ and R⁵ independently represent hydrogen, methyl or ethyl. A particular value of
30 R³ is C₁₋₆ alkyl, especially methyl.

A particular sub-class of compounds according to the invention is represented by the compounds of formula II, and salts and prodrugs thereof:



5

(II)

wherein

Y^1 represents a methylene (CH_2) or carbonyl ($C=O$) linkage;

10 R^{13} represents hydrogen, halogen, cyano, nitro, trifluoromethyl, pyrrolyl, furyl, isoxazolyl, amino, C_{1-6} alkylamino, di(C_{1-6})alkylamino, C_{1-6} alkyl, C_{1-6} alkoxy, C_{2-6} alkylcarbonyl, C_{1-6} alkylsulphonyl or $-CR^4=NOR^5$; and

R^4 and R^5 independently represent hydrogen, methyl or ethyl.

Suitably, Y^1 represents a carbonyl ($C=O$) linkage.

15 Suitably, R^{13} represents C_{1-6} alkyl, especially methyl.

Specific compounds within the scope of the present invention include:

- 1-[3-(morpholin-4-ylcarbonyl)phenyl]-5-methylbenzimidazole;
- 1-[3-(*N,N*-diethylamido)phenyl]-5-methylbenzimidazole;
- 20 1-[3-(4-pyridylmethylamido)phenyl]-5-methylbenzimidazole;
- 1-[3-(2-pyridylmethylamido)phenyl]-5-methylbenzimidazole;
- 1-[3-(thiomorpholin-4-ylcarbonyl)phenyl]-5-methylbenzimidazole;
- 1-[3-(4-hydroxypiperidin-1-ylcarbonyl)phenyl]-5-methylbenzimidazole;
- 1-[3-(morpholin-4-ylmethyl)phenyl]-5-methylbenzimidazole;
- 25 1-[3-(imidazol-1-ylmethyl)phenyl]-5-methylbenzimidazole;

and salts and prodrugs thereof.

Also provided by the present invention is a method for the treatment and/or prevention of anxiety which comprises administering to a patient in need of such treatment an effective amount of a compound of formula I as defined above or a pharmaceutically acceptable salt thereof.

Further provided by the present invention is a method for the treatment and/or prevention of convulsions (e.g. in a patient suffering from epilepsy or a related disorder) which comprises administering to a patient in need of such treatment an effective amount of a compound of formula I as defined above or a pharmaceutically acceptable salt thereof.

The binding affinity (K_i) of the compounds according to the present invention for the $\alpha 3$ subunit of the human GABA_A receptor is conveniently as measured in the assay described hereinbelow. The $\alpha 3$ subunit binding affinity (K_i) of the compounds of the invention is ideally 10 nM or less, preferably 2 nM or less, and more preferably 1 nM or less.

The compounds according to the present invention will ideally elicit at least a 40%, preferably at least a 50%, and more preferably at least a 60%, potentiation of the GABA EC₂₀ response in stably transfected recombinant cell lines expressing the $\alpha 3$ subunit of the human GABA_A receptor. Moreover, the compounds of the invention will ideally elicit at most a 30%, preferably at most a 20%, and more preferably at most a 10%, potentiation of the GABA EC₂₀ response in stably transfected recombinant cell lines expressing the $\alpha 1$ subunit of the human GABA_A receptor.

The potentiation of the GABA EC₂₀ response in stably transfected cell lines expressing the $\alpha 3$ and $\alpha 1$ subunits of the human GABA_A receptor can conveniently be measured by procedures analogous to the protocol described in Wafford *et al.*, *Mol. Pharmacol.*, 1996, 50, 670-678. The procedure will suitably be carried out utilising cultures of stably transfected eukaryotic cells, typically of stably transfected mouse Ltk⁻ fibroblast cells.

The compounds according to the present invention exhibit anxiolytic activity, as demonstrated by a positive response in the elevated plus maze and conditioned suppression of drinking tests (cf. Dawson *et al.*, *Psychopharmacology*, 1995, 121, 109-117). Moreover, the compounds of 5 the invention are substantially non-sedating, as confirmed by an appropriate result obtained from the response sensitivity (chain-pulling) test (cf. Bayley *et al.*, *J. Psychopharmacol.*, 1996, 10, 206-213).

The compounds according to the present invention may also exhibit anticonvulsant activity. This can be demonstrated by the ability to block 10 pentylenetetrazole-induced seizures in rats and mice, following a protocol analogous to that described by Bristow *et al.* in *J. Pharmacol. Exp. Ther.*, 1996, 279, 492-501.

In order to elicit their behavioural effects, the compounds of the 15 invention will ideally be brain-penetrant; in other words, these compounds will be capable of crossing the so-called "blood-brain barrier". Preferably, the compounds of the invention will be capable of exerting their beneficial therapeutic action following administration by the oral route.

The invention also provides pharmaceutical compositions comprising one or more compounds of this invention in association with a 20 pharmaceutically acceptable carrier. Preferably these compositions are in unit dosage forms such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, auto-injector devices or suppositories; for oral, parenteral, intranasal, sublingual or rectal administration, or for 25 administration by inhalation or insufflation. For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical 30 diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a

pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. Typical unit dosage forms contain from 1 to 100 mg, for example 1, 2, 5, 10, 25, 50 or 100 mg, of the active ingredient. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.


The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin.

In the treatment of anxiety, a suitable dosage level is about 0.01 to 30 250 mg/kg per day, preferably about 0.05 to 100 mg/kg per day, and

especially about 0.05 to 5 mg/kg per day. The compounds may be administered on a regimen of 1 to 4 times per day.

The compounds in accordance with the present invention may be prepared by a process which comprises reacting a compound of formula III:


5



(III)

wherein Y, R¹, R² and R³ are as defined above; with formic acid, typically at an elevated temperature.

10 In another procedure, the compounds according to the present invention in which Y represents a methylene linkage may be prepared by a process which comprises treating a compound of formula IV:



(IV)


15

wherein R¹, R² and R³ are as defined above; with a reducing agent such as lithium aluminium hydride.


In a further procedure, the compounds according to the present invention in which Y represents a thiocarbonyl linkage may be prepared

by a process which comprises treating the corresponding compound of formula IV as defined above with Lawesson's reagent [2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulphide] or phosphorus pentasulphide in a suitable solvent, e.g. pyridine, at ambient
 5 or elevated temperatures, suitably at the reflux temperature of the solvent.

In a yet further procedure, the compounds according to the present invention in which Y represents a methylene linkage may be prepared by a process which comprises reacting a compound of formula V with a
 10 compound of formula VI:



(V)




(VI)

wherein R^1 , R^2 and R^3 are as defined above, and L represents a suitable
 15 leaving group.

The leaving group L is suitably a halogen atom, e.g. chloro, in which case the reaction between compounds V and VI is conveniently carried out by stirring the reactants in a suitable solvent, for example *N,N*-dimethylformamide, tetrahydrofuran, acetonitrile or dichloromethane,
 20 optionally in the presence of a base such as potassium carbonate or triethylamine.

In a still further procedure, the compounds according to the invention in which Y represents a carbonyl linkage, i.e. the compounds of formula IV as defined above, may be prepared by a process which comprises reacting a compound of formula VI as defined above with a
 25 compound of formula VII:



wherein R³ is as defined above, and Q represents a reactive carboxylate moiety.

Suitable values for the reactive carboxylate moiety Q include esters, for example C₁₋₄ alkyl esters; acid anhydrides, for example mixed anhydrides with C₁₋₄ alkanoic acids; acid halides, for example acid chlorides; and acylimidazoles.


By way of example, the intermediates of formula VII above wherein Q is an acid chloride moiety may be prepared by treating the corresponding carboxylic acid derivative with thionyl chloride in toluene. Similarly, the intermediates of formula VII wherein Q is an acylimidazole moiety may be prepared by treating the corresponding carboxylic acid derivative with 1,1'-carbonyldiimidazole. Alternatively, the reactive carboxylate moiety Q may be obtained by treating the corresponding compound wherein Q is carboxy with 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and 1-hydroxybenzotriazole hydrate, optionally in the presence of triethylamine; the resulting activated carboxylate intermediate may then suitably be reacted *in situ* with the required compound of formula VI.

Typical intermediates of formula V above wherein the leaving group L is a halogen atom may suitably be prepared by treating the appropriate compound of formula VII wherein Q represents carboxy with a reducing agent, for example lithium aluminium hydride, followed by conversion of

the primary hydroxy group in the compound thereby obtained into a halogen atom by treatment with a thionyl halide such as thionyl chloride.

The intermediates of formula VII above may suitably be prepared by reacting a compound of formula VIII:

5



(VIII)

wherein R³ and Q are as defined above; with formic acid, typically at an elevated temperature.

10 The intermediates of formula III and VIII above may be prepared by methods analogous to those described in EP-A-0616807.

Where they are not commercially available, the starting materials of formula VI may be prepared by methods analogous to those described in the accompanying Examples, or by standard methods well known from the art.

15 It will be understood that any compound of formula I initially obtained from any of the above processes may, where appropriate, subsequently be elaborated into a further compound of formula I by techniques known from the art. Indeed, as noted above, the intermediates of formula IV are compounds according to the invention in their own right.

20 Where the above-described processes for the preparation of the compounds according to the invention give rise to mixtures of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography. The novel compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution. The novel compounds

may, for example, be resolved into their component enantiomers by standard techniques such as preparative HPLC, or the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di-*p*-toluoyl-d-tartaric acid and/or (+)-di-*p*-toluoyl-l-tartaric acid,
5 followed by fractional crystallization and regeneration of the free base. The novel compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary.

During any of the above synthetic sequences it may be necessary
10 and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in *Protective Groups in Organic Chemistry*, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, *Protective Groups in Organic Synthesis*, John Wiley & Sons,
15 1991. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.

The following Examples illustrate the preparation of compounds according to the invention.

The compounds in accordance with this invention potently inhibit
20 the binding of [³H]-flumazenil to the benzodiazepine binding site of human GABA_A receptors containing the α2 or α3 subunit stably expressed in Ltk-cells.

Reagents

- 25 • Phosphate buffered saline (PBS).
- Assay buffer: 10 mM KH₂PO₄, 100 mM KCl, pH 7.4 at room temperature.
- [³H]-Flumazenil (18 nM for α1β3γ2 cells; 18 nM for α2β3γ2 cells; 10 nM for α3β3γ2 cells) in assay buffer.
- Flunitrazepam 100 μM in assay buffer.
- 30 • Cells resuspended in assay buffer (1 tray to 10 ml).

Harvesting Cells

Supernatant is removed from cells. PBS (approximately 20 ml) is added. The cells are scraped and placed in a 50 ml centrifuge tube. The 5 procedure is repeated with a further 10 ml of PBS to ensure that most of the cells are removed. The cells are pelleted by centrifuging for 20 min at 3000 rpm in a benchtop centrifuge, and then frozen if desired. The pellets are resuspended in 10 ml of buffer per tray (25 cm x 25 cm) of cells.

10 *Assay*

Can be carried out in deep 96-well plates or in tubes. Each tube contains:

- 300 µl of assay buffer.
- 50 µl of [³H]-flumazenil (final concentration for $\alpha 1\beta 3\gamma 2$: 1.8 nM; for $\alpha 2\beta 3\gamma 2$: 1.8 nM; for $\alpha 3\beta 3\gamma 2$: 1.0 nM).
- 50 µl of buffer or solvent carrier (e.g. 10% DMSO) if compounds are dissolved in 10% DMSO (total); test compound or flunitrazepam (to determine non-specific binding), 10 µM final concentration.
- 100 µl of cells.

20 Assays are incubated for 1 hour at 40°C, then filtered using either a Tomtec or Brandel cell harvester onto GF/B filters followed by 3 x 3 ml washes with ice cold assay buffer. Filters are dried and counted by liquid scintillation counting. Expected values for total binding are 3000-4000 dpm for total counts and less than 200 dpm for non-specific binding if 25 using liquid scintillation counting, or 1500-2000 dpm for total counts and less than 200 dpm for non-specific binding if counting with meltilex solid scintillant. Binding parameters are determined by non-linear least squares regression analysis, from which the inhibition constant K_i can be calculated for each test compound.

30 The compounds of the accompanying Examples were tested in the above assay, and all were found to possess a K_i value for displacement of

[³H]-flumazenil from the α 2 and/or α 3 subunit of the human GABA_A receptor of 100 nM or less.

EXAMPLE 1

5

1-[3-(Morpholin-4-ylcarbonyl)phenyl]-5-methylbenzimidazole

Step 1: 4-Methyl-3'-carboxy-2-nitrodiphenylamine

4-Methyl-2-nitroaniline, 3-iodobenzoic acid (10 g, 40 mmol),
10 potassium carbonate (5.5 g, 40 mmol) and a catalytic amount of CuI were
thoroughly mixed and heated to 230°C for 4 hours. The reaction mixture
was allowed to cool to 100°C and water added. After cooling to room
temperature the solution was rendered acidic by careful addition of glacial
acetic acid. The precipitate was filtered off and washed with
15 dichloromethane. Recrystallization from 2-propanol afforded product.
Yield 4.3 g.

Step 2: 2-Amino-3'-carboxy-4-methyldiphenylamine

A mixture of 4-methyl-3'-carboxy-2-nitrodiphenylamine (1 g, 3.11
20 mmol) and palladium on activated carbon (5%, 0.1 g) in MeOH (25 ml) was
hydrogenated at ambient pressure until the hydrogen uptake had ceased.
The reaction mixture was filtered through celite into a few millilitres of
ethereal hydrogen chloride. Evaporation of solvent left the desired product
(0.95 g, 2.89 mmol).

25

Step 3: 1-(3-Carboxyphenyl)-5-methylbenzimidazole

A mixture of 2-amino-3'-carboxy-4-methyldiphenylamine (6.00 g,
14.4 mmol) and formic acid (60 ml) was refluxed for 16h. After
evaporation to dryness, the residue was dissolved in ethyl acetate (100 ml)
30 and washed with water (100 ml). The organic phase was dried and
evaporated. The crude product was purified by column chromatography

with methylene chloride as the eluent. Yield 4.2 g. ^1H NMR (250MHz, DMSO) δ 2.47 (3H, s), 7.21 (1H, dd, $J=1.4\text{Hz}$), 7.53 (1H, d, $J=8.3\text{Hz}$), 7.60 (1H, s), 7.75 (1H, t, $J=7.8\text{Hz}$), 7.95 (1H, m), 8.03 (1H, m), 8.14 (1H, m) and 8.62 (1H, s). MS M^+ 253.

5

Step 4: 1-[3-(Morpholin-4-ylcarbonyl)phenyl]-5-methylbenzimidazole

A mixture of 1-(3-carboxyphenyl)-5-methylbenzimidazole (50 mg, 0.19 mM), 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide, HCl (76 mg, 0.39 mM), hydroxybenzotriazole (53 mg, 0.39 mM) in dimethylformamide 10 (2 ml) was treated with triethylamine (80 μl , 0.39 mM) and morpholine (20 μl , 0.22 mM) and the reaction stirred for 18 hours at room temperature under N_2 . Dilution with water and extractive work up with ethyl acetate was followed by chromatography on silica gel. Yield 37 mg. ^1H NMR (360MHz, DMSO) 2.51 (3H, s), 3.47-3.73 (8H, m), 7.16 (1H, d, $J=8.3\text{ Hz}$), 15 7.41 (1H, d, $J=8.3\text{Hz}$), 7.45 and 7.47 (1H, dt, $J=1.4\text{Hz}$, 7.0Hz), 7.57-7.60 (3H, m), 7.66 (1H, s) and 8.08 (1H, s). MS M^+ 322.

EXAMPLE 2

20 **1-[3-(*N,N*-Diethylamido)phenyl]-5-methylbenzimidazole**

Prepared by an analogous procedure to that described in Example 1 using diethylamine. ^1H NMR (360MHz, CDCl_3) 1.10-1.24 (6H, m), 2.51 (3H, s), 3.27-3.42 (2H, m), 3.50-3.64 (2H, m), 7.16 (1H, d, $J=8.3\text{Hz}$), 7.42-7.45 (2H, m), 7.53-7.62 (3H, m), 7.66 (1H, s) and 8.08 (1H, s). MS M^+ 308.

25

EXAMPLE 3

1-[3-(4-Pyridylmethylamido)phenyl]-5-methylbenzimidazole

Prepared by an analogous procedure to that described in Example 1 30 using 4-pyridylmethylamine. ^1H NMR (360MHz, CDCl_3) 2.44 (3H, s), 4.68 (2H, d, $J=5.9\text{Hz}$), 7.09 (1H, d, $J=8.3\text{Hz}$), 7.25 (1H, d, $J=6.0\text{Hz}$), 7.35 (1H, d,

J=8.3Hz), 7.49 (1H, s), 7.61-7.66 (2H, m), 7.88 (1H, s), 7.97-8.01 (2H, m), 8.16 (1H, br t) and 8.49 (2H, m). MS M⁺ 343.

EXAMPLE 4

5

1-[3-(2-Pyridylmethylamido)phenyl]-5-methylbenzimidazole

Prepared by an analogous procedure to that described in Example 1 using 2-pyridylmethylamine. ¹H NMR (250MHz, DMSO) 2.45 (3H, s), 4.61 (2H, d, J=5.9Hz), 7.19 (1H, d, J=8.7Hz), 7.26 (1H, dd, J=4.8 and 12.3Hz), 10 7.36 (1H, d, J=7.8Hz), 7.55-7.59 (2H, m), 7.71-7.80 (2H, m), 7.88 (1H, d, J=8.9Hz), 7.99-8.02 (1H, d, J=7.7Hz), 8.18 (1H, s), 8.30-8.35 (1H, m), 8.58 (1H, s) and 9.30 (1H, br t, J=5.9Hz). MS M⁺ 343.

EXAMPLE 5

15

1-[3-(Thiomorpholin-4-ylcarbonyl)phenyl]-5-methylbenzimidazole

Prepared by an analogous procedure to that described in Example 1 using thiomorpholine. ¹H NMR (250MHz, DMSO) 2.45 (3H, s), 2.67 (4H, br s), 3.63 (2H, br), 3.88 (2H, br), 7.18 (1H, d, J=8.3Hz), 7.46-7.57 (3H, m), 20 7.66-7.78 (3H, m) and 8.55 (1H, s). MS M⁺ 338.

EXAMPLE 6

1-[3-(4-Hydroxypiperidin-1-ylcarbonyl)phenyl]-5-methylbenzimidazole

25 Prepared by an analogous procedure to that described in Example 1 using 4-hydroxypiperidine. ¹H NMR (250MHz, DMSO) 1.39 (2H, br), 1.77 (2H, br), 2.45 (3H, s), 3.24 (1H, br), 3.52 (2H, br), 3.72 (2H, br), 4.82 (1H, d, J=3.9Hz), 7.17 (1H, d, J=8.3Hz), 7.45-7.57 (3H, m), 7.65-7.74 (3H, m) and 8.54 (1H, s). MS M⁺ 336.

30

-23-

EXAMPLE 7

1-[3-(Morpholin-4-ylmethyl)phenyl]-5-methylbenzimidazole

5 Step 1: 1-(3-Hydroxymethylphenyl)-5-methylbenzimidazole

1-(3-Carboxyphenyl)-5-methylbenzimidazole (2 g, 0.079 mM) was dissolved in dry tetrahydrofuran (100 ml) and cooled to 0°C. Lithium aluminium hydride (7.9 ml, 1.0M solution) was added dropwise over 10 minutes. After complete addition the reaction was heated to reflux for 4 hours. The reaction was cooled and quenched by addition of water (2 ml) and 2N sodium hydroxide (4 ml). The reaction was diluted with ethyl acetate and filtered through hyflo, washing with ethyl acetate. Dried over magnesium sulphate and evaporated (1.2 g). MS M⁺ 239.

15 Step 2: 1-(3-Chloromethylphenyl)-5-methylbenzimidazole HCl

1-(3-Hydroxymethylphenyl)-5-methylbenzimidazole (0.3 g, 1.26 mM) was dissolved in dichloromethane (3 ml). Thionyl chloride (92 µl, 1.26 mM) was added and the reaction stirred for 30 minutes. Solvent evaporated to obtain product (0.36 g). MS M⁺ 257.

20

Step 3: 1-[3-(Morpholin-4-ylmethyl)phenyl]-5-methylbenzimidazole

1-(3-Chloromethyl)phenyl-5-methylbenzimidazole (0.11 g, 0.37 mM) was dissolved in dimethylformamide (5 ml). Potassium carbonate (52 mg, 0.37 mM) was added followed by morpholine (97 µl, 1.11 mM) and the reaction heated to 80°C for 18 hours. Dilution with water and extraction with ethyl acetate was followed by chromatography over silica gel (61 mg). ¹H NMR (360MHz, DMSO, TFA) 2.54 (3H, s), 3.17 (2H, br), 3.31 (2H, br), 3.18 (2H, br), 3.95 (2H, br), 4.50 (2H, s), 7.49 (1H, d, J=5.7Hz), 7.78-7.94 (5H, m), 8.08 (1H, s) and 9.94 (1H, s). MS M⁺ 308.


30

EXAMPLE 81-[3-(Imidazol-1-ylmethyl)phenyl]-5-methylbenzimidazole

1-(3-Chloromethylphenyl)-5-methylbenzimidazole (0.1 g, 0.34 mM)
5 was dissolved in dichloromethane (5 ml), imidazole (92 mg, 1.36 mM) was added and the reaction heated to reflux for 18 hours, then diluted with water and extracted into ethyl acetate, dried (MgSO_4) and purified by silica chromatography. Yield 34 mg. ^1H NMR (250MHz, DMSO) δ 2.44 (3H, s), 5.32 (2H, s), 6.92 (1H, t, $J=0.9\text{Hz}$), 7.16 (1H, d, $J=8.3\text{Hz}$), 7.29-7.35 (2H, m), 7.47 (1H, d, $J=8.3\text{Hz}$), 7.57-7.61 (4H, m), 7.83 (1H, t, $J=0.9\text{Hz}$) and 8.49 (1H, s). MS m/e 289.

CLAIMS:

1. A compound of formula I, or a salt or prodrug thereof:



5

(I)

wherein


Y represents a methylene (CH_2), carbonyl ($\text{C}=\text{O}$) or thiocarbonyl ($\text{C}=\text{S}$) linkage;

10 R^1 and R^2 independently represent hydrogen, hydrocarbon or a heterocyclic group; or R^1 and R^2 , together with the intervening nitrogen atom, represent an optionally substituted heterocyclic ring selected from azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl and imidazolyl;

15 R^3 represents hydrogen, hydrocarbon, a heterocyclic group, halogen, cyano, trifluoromethyl, nitro, $-\text{OR}^{\text{a}}$, $-\text{SR}^{\text{a}}$, $-\text{SOR}^{\text{a}}$, $-\text{SO}_2\text{R}^{\text{a}}$, $-\text{SO}_2\text{NR}^{\text{a}}\text{R}^{\text{b}}$, $-\text{NR}^{\text{a}}\text{R}^{\text{b}}$, $-\text{NR}^{\text{a}}\text{COR}^{\text{b}}$, $-\text{NR}^{\text{a}}\text{CO}_2\text{R}^{\text{b}}$, $-\text{COR}^{\text{a}}$, $-\text{CO}_2\text{R}^{\text{a}}$, $-\text{CONR}^{\text{a}}\text{R}^{\text{b}}$ or $-\text{CR}^{\text{a}}=\text{NOR}^{\text{b}}$; and

20 R^{a} and R^{b} independently represent hydrogen, hydrocarbon or a heterocyclic group.

2. A compound as claimed in claim 1 represented by formula II, and salts and prodrugs thereof:



wherein

Y^1 represents a methylene (CH_2) or carbonyl ($C=O$) linkage;

5 R^{13} represents hydrogen, halogen, cyano, nitro, trifluoromethyl, pyrrolyl, furyl, isoxazolyl, amino, C_{1-6} alkylamino, di(C_{1-6})alkylamino, C_{1-6} alkyl, C_{1-6} alkoxy, C_{2-6} alkylcarbonyl, C_{1-6} alkylsulphonyl or $-CR^4=NOR^5$; and

10 R^4 and R^5 independently represent hydrogen, methyl or ethyl.

10

3. A compound as claimed in claim 2 wherein Y^1 represents a carbonyl ($C=O$) linkage.

15 4. A compound as claimed in claim 2 or claim 3 wherein R^{13} represents C_{1-6} alkyl.

5. A compound selected from:

1-[3-(morpholin-4-ylcarbonyl)phenyl]-5-methylbenzimidazole;
 1-[3-(*N,N*-diethylamido)phenyl]-5-methylbenzimidazole;
 20 1-[3-(4-pyridylmethylamido)phenyl]-5-methylbenzimidazole;
 1-[3-(2-pyridylmethylamido)phenyl]-5-methylbenzimidazole;
 1-[3-(thiomorpholin-4-ylcarbonyl)phenyl]-5-methylbenzimidazole;
 1-[3-(4-hydroxypiperidin-1-ylcarbonyl)phenyl]-5-methylbenzimidazole;
 1-[3-(morpholin-4-ylmethyl)phenyl]-5-methylbenzimidazole;
 25 and salts and prodrugs thereof.

6. A compound selected from:

1-[3-(imidazol-1-ylmethyl)phenyl]-5-methylbenzimidazole;
and salts and prodrugs thereof.

5

7. A pharmaceutical composition comprising a compound of formula I as defined in claim 1 or a pharmaceutically acceptable salt thereof or a prodrug thereof in association with a pharmaceutically acceptable carrier.

10

8. The use of a compound as claimed in any one of claims 1 to 6 for the manufacture of a medicament for the treatment and/or prevention of anxiety.


15

9. The use of a compound as claimed in any one of claims 1 to 6 for the manufacture of a medicament for the treatment and/or prevention of convulsions.

20

10. A process for the preparation of a compound as claimed in claim 1, which comprises:


(A) reacting a compound of formula III:



(III)

wherein Y, R¹, R² and R³ are as defined in claim 1; with formic acid; or

(B) treating a compound of formula IV:




5

(IV)

wherein R¹, R² and R³ are as defined in claim 1; with a reducing agent; or


10 (C) treating a compound of formula IV as defined above with
Lawesson's reagent or phosphorus pentasulphide; or

(D) reacting a compound of formula V with a compound of formula VI:



15


(V)



(VI)

wherein R¹, R² and R³ are as defined in claim 1, and L represents a suitable leaving group; or

(E) reacting a compound of formula VI as defined above with a compound of formula VII:



(VII)

5

wherein R³ is as defined in claim 1, and Q represents a reactive carboxylate moiety; and

10 (F) if desired, converting a compound of formula I initially obtained
into a further compound of formula I by standard methods.

11. A method for the treatment and/or prevention of anxiety
which comprises administering to a patient in need of such treatment an
effective amount of a compound of formula I as defined in claim 1 or a
15 pharmaceutically acceptable salt thereof or a prodrug thereof.

12. A method for the treatment and/or prevention of convulsions
which comprises administering to a patient in need of such treatment an
effective amount of a compound of formula I as defined in claim 1 or a
20 pharmaceutically acceptable salt thereof or a prodrug thereof.

INTERNATIONAL SEARCH REPORT

Int'l Application No

PCT/GB 98/00322

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D235/06 C07D401/10 C07D403/10 A61K31/445 A61K31/415
 //((C07D401/10,235:00,211:00),(C07D403/10,235:00,233:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| X | EP 0 563 001 A (NEUROSEARCH AS) 29 September 1993 see example 52A --- | 1,7-9 |
| Y | EP 0 616 807 A (NEUROSEARCH AS ;MEIJI SEIKA KAISHA (JP)) 28 September 1994 cited in the application see example 40A; table 1 --- | 1-9 |
| Y | WO 96 33191 A (NEUROSEARCH AS ;MEIJI SEIKA KAISHA (JP); TEUBER LENE (DK); WAETJEN) 24 October 1996 see the whole document --- | 1-9 |
| Y | WO 96 33194 A (NEUROSEARCH AS ;MEIJI SEIKA KAISHA (JP); TEUBER LENE (DK); WAETJEN) 24 October 1996 see the whole document --- | 1-9 |
| | -/- | |

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

| | |
|---|--|
| Date of the actual completion of the international search | Date of mailing of the international search report |
| 2 June 1998 | 03.07.98 |
| Name and mailing address of the ISA | Authorized officer |
| European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016 | Frelon, D |

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/00322

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|----------|--|-----------------------|
| A | FR 2 043 471 A (ROUSSEL UCLAF) 19 February 1971 see page 1, line 13 - line 17 ----- | 1,7-9 |
| A | EP 0 607 076 A (SYNTHELABO) 20 July 1994 see abstract ----- | 1,7-9 |

INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB 98/00322

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 11 and 12

because they relate to subject matter not required to be searched by this Authority, namely:

Remark: Although claims 11 and 12

are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. Claims Nos.:

because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. Claims Nos.:

because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/00322

| Patent document cited in search report | Publication date | Patent family member(s) | | Publication date |
|--|------------------|-------------------------|--|------------------|
| EP 0563001 | A 29-09-1993 | AT 134621 T | | 15-03-1996 |
| | | AU 3540693 A | | 30-09-1993 |
| | | CA 2092211 A | | 27-09-1993 |
| | | DE 69301618 D | | 04-04-1996 |
| | | DE 69301618 T | | 22-08-1996 |
| | | DK 563001 T | | 05-08-1996 |
| | | ES 2085133 T | | 16-05-1996 |
| | | FI 931305 A | | 27-09-1993 |
| | | JP 6049037 A | | 22-02-1994 |
| | | NZ 247233 A | | 28-03-1995 |
| | | US 5360809 A | | 01-11-1994 |
| | | ZA 9302090 A | | 15-10-1993 |
| EP 0616807 | A 28-09-1994 | AU 675484 B | | 06-02-1997 |
| | | AU 5752194 A | | 29-09-1994 |
| | | CA 2119511 A | | 25-09-1994 |
| | | CN 1099391 A | | 01-03-1995 |
| | | FI 941378 A | | 25-09-1994 |
| | | JP 7002838 A | | 06-01-1995 |
| | | NO 941052 A | | 26-09-1994 |
| | | NZ 260050 A | | 26-01-1996 |
| | | US 5554632 A | | 10-09-1996 |
| | | US 5554630 A | | 10-09-1996 |
| | | ZA 9402079 A | | 24-10-1994 |
| WO 9633191 | A 24-10-1996 | AU 5501496 A | | 07-11-1996 |
| | | AU 5689196 A | | 07-11-1996 |
| | | AU 5690696 A | | 07-11-1996 |
| | | CZ 9703291 A | | 18-03-1998 |
| | | CZ 9703292 A | | 18-03-1998 |
| | | WO 9633194 A | | 24-10-1996 |
| | | WO 9633192 A | | 24-10-1996 |
| | | EP 0821683 A | | 04-02-1998 |
| | | EP 0821684 A | | 04-02-1998 |
| | | EP 0821682 A | | 04-02-1998 |
| | | NO 974843 A | | 15-12-1997 |
| | | NO 974844 A | | 16-12-1997 |
| | | PL 322892 A | | 02-03-1998 |
| | | PL 322944 A | | 02-03-1998 |

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/00322

| Patent document cited in search report | | Publication date | Patent family member(s) | Publication date |
|--|---|------------------|--|--|
| WO 9633194 | A | 24-10-1996 | AU 5501496 A AU 5689196 A AU 5690696 A CZ 9703291 A CZ 9703292 A WO 9633191 A WO 9633192 A EP 0821683 A EP 0821684 A EP 0821682 A NO 974843 A NO 974844 A PL 322892 A PL 322944 A | 07-11-1996 07-11-1996 07-11-1996 18-03-1998 18-03-1998 24-10-1996 24-10-1996 04-02-1998 04-02-1998 04-02-1998 15-12-1997 16-12-1997 02-03-1998 02-03-1998 |
| FR 2043471 | A | 19-02-1971 | NONE | |
| EP 607076 | A | 20-07-1994 | FR 2700544 A FR 2707987 A AU 665137 B AU 5317794 A CA 2113490 A CN 1097743 A CZ 9400093 A FI 940186 A HU 70407 A JP 6271575 A NO 940130 A NZ 250679 A PL 301901 A SK 4694 A US 5466706 A ZA 9400291 A | 22-07-1994 27-01-1995 14-12-1995 25-05-1995 16-07-1994 25-01-1995 17-08-1994 16-07-1994 30-10-1995 27-09-1994 18-07-1994 26-07-1995 25-07-1994 08-02-1995 14-11-1995 17-08-1994 |